AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress
STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure with reduced ejection fraction (HFrEF) have been selected for presentation in the Late-Breaking Science program at the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) 2026 […]